Search
forLearn
5 / 801 resultslearn K&B
learn KB solution
learn PTD-DBM
learn riboflavin
Research
5 / 22 results
research Obsessive-compulsive skin disorders: a novel classification based on degree of insight
The new classification system for skin disorders emphasizes the importance of understanding a patient's awareness of their condition for better treatment.
research Cross-sectional survey examining skin picking and hair pulling disorders during the COVID-19 pandemic
The COVID-19 pandemic increased symptoms in people with skin picking and hair pulling disorders.
research An Unusual Compulsive Behavior Related to Scalp Psoriasis and Hair Follicle Anxiety in Young Men
Young men with scalp psoriasis and hair loss fears may develop compulsive scalp behaviors needing attention.
research Dermatologists’ Role in Interdisciplinary Care for Obsessive-Compulsive Disorder and Body-Focused Repetitive Behaviors
Dermatologists are key in detecting and managing OCD and BFRBs by working with psychiatrists.
research Body-focused repetitive behaviors and the dermatology patient
Skin and hair-picking disorders are common and need both skin and mental health treatments.
Community Join
5 / 1000+ resultscommunity Efficacy and Tolerability of N-Acetyl-Cysteine for Treatment of The Early-onset Androgenetic Alopecia in Men
N-Acetyl-Cysteine (NAC) was found to improve hair parameters in men with early-onset androgenetic alopecia, showing increased terminal hair count and decreased vellus hair count, with good tolerability. NAC, used alone or with minoxidil, may help due to its antioxidant properties, though its effectiveness can vary among individuals.
community IGFBP‐rP1 is a potential therapeutic target in androgenic alopecia
IGFBP‐rP1 shows potential for treating androgenic alopecia by influencing hair cycle transitions. Increasing IGF-1 levels may have similar effects to Minoxidil and 5-AR inhibitors in reducing hair loss.
community Group Buy for MR antagonist finerenone
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
community How long still for CB-03-01? (breezula)
The conversation is about the release timeline for clinical trial results and the availability of Breezula, a hair loss treatment. The user is not comfortable buying it as a research drug from China.
community Finasteride alternative close to fda approval in the US
Breezula, a topical treatment, is anticipated to be available in the US by mid-2027 as a potential alternative to finasteride with fewer systemic side effects. There is ongoing debate about its effectiveness and some users report similar side effects to finasteride.